Neurosense Therapeutics Ltd (NRSN)
$1.26
+0.04
(+3.28%)▲
Performance
- $1.22$1.28$1.26
3.17%
Downside
Day's Volatility :4.68%
Upside
1.56%
- $0.40$2.33$1.26
68.25%
Downside
52 Weeks Volatility :82.83%
Upside
45.92%
Returns
| Period | Neurosense Therapeutics Ltd | Index (Russel 2000) |
|---|---|---|
3 Months | 6.1% | 0.0% |
6 Months | -29.89% | 0.0% |
1 Year | 101.45% | 0.0% |
3 Years | -69.8% | -20.1% |
Highlights
Market Capitalization | 23.6M |
Book Value | - $0.09 |
Earnings Per Share (EPS) | -0.65 |
Wall Street Target Price | 5.25 |
Profit Margin | 0.0% |
Operating Margin TTM | 0.0% |
Return On Assets TTM | -150.79% |
Return On Equity TTM | -494.84% |
Revenue TTM | 0.0 |
Revenue Per Share TTM | 0.0 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 0.0 |
EBITDA | -11.7M |
Diluted Eps TTM | -0.65 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -0.9 |
EPS Estimate Next Year | -0.7 |
EPS Estimate Current Quarter | -0.2 |
EPS Estimate Next Quarter | -0.19 |
Analyst Recommendation
- Current
- 1M Ago
- 3M Ago
Analyst Forecast
What analysts predicted
Upside of 316.67%
Technicals Summary
Sell
Neutral
Buy
Neurosense Therapeutics Ltd is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Peers
| Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
|---|---|---|---|---|---|
 Neurosense Therapeutics Ltd | 29.61% | -29.89% | 101.45% | -69.8% | -69.8% |
 Regeneron Pharmaceuticals, Inc. | -10.33% | 8.11% | 21.28% | 85.63% | 257.49% |
 Novo Nordisk A/s | -12.25% | -9.71% | 24.92% | 138.38% | 343.21% |
 Alnylam Pharmaceuticals, Inc. | 9.22% | 72.73% | 52.35% | 34.04% | 250.13% |
 Vertex Pharmaceuticals Incorporated | -3.09% | 12.2% | 25.77% | 150.7% | 163.62% |
| Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
|---|---|---|---|---|---|---|---|---|
Neurosense Therapeutics Ltd | NA | NA | NA | -0.9 | -4.95 | -1.51 | NA | -0.09 |
Regeneron Pharmaceuticals, Inc. | 27.55 | 27.55 | 1.42 | 45.05 | 0.17 | 0.08 | NA | 261.41 |
Novo Nordisk A/s | 38.7 | 38.7 | 1.75 | 3.41 | 0.89 | 0.23 | 0.01 | 25.24 |
Alnylam Pharmaceuticals, Inc. | NA | NA | -0.49 | -2.49 | -15.01 | 0.02 | NA | -0.02 |
Vertex Pharmaceuticals Incorporated | 32.84 | NA | 0.55 | 0.32 | -0.03 | 0.13 | NA | 57.26 |
| Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
|---|---|---|---|---|---|
Neurosense Therapeutics Ltd | Buy | $23.6M | -69.8% | NA | 0.0% |
Regeneron Pharmaceuticals, Inc. | Buy | $114.7B | 257.49% | 27.55 | 32.04% |
Novo Nordisk A/s | Buy | $518.0B | 343.21% | 38.7 | 34.84% |
Alnylam Pharmaceuticals, Inc. | Buy | $34.9B | 250.13% | NA | -3.11% |
Vertex Pharmaceuticals Incorporated | Buy | $119.3B | 163.62% | 32.84 | -4.74% |
Institutional Holdings
Armistice Capital, LLC
8.14%Meitav Dash Investments Ltd
0.21%XTX Topco Ltd
0.17%Morgan Stanley - Brokerage Accounts
0.01%CWM, LLC duplicate
0.01%
Company Information
advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa
Organization | Neurosense Therapeutics Ltd |
Employees | 18 |
CEO | Mr. Alon Ben-Noon |
Industry | Miscellaneous |
Discover More
Graniteshares 2x Long Baba Daily Etf
$1.26
+3.28%
Mingteng International Corp Inc
$1.26
+3.28%
Direct Digital Holdings Inc
$1.26
+3.28%
Dt Cloud Star Acquisition Corporation Right
$1.26
+3.28%
Precipio Inc
$1.26
+3.28%
Venus Concept Inc
$1.26
+3.28%
Fidelity Msci Materials Etf
$1.26
+3.28%
Inspire International Etf
$1.26
+3.28%
First Trust Dorsey Wright Momentum & Value Etf
$1.26
+3.28%